HK1107768A1 - Solid drug for oral use - Google Patents

Solid drug for oral use

Info

Publication number
HK1107768A1
HK1107768A1 HK08101016.0A HK08101016A HK1107768A1 HK 1107768 A1 HK1107768 A1 HK 1107768A1 HK 08101016 A HK08101016 A HK 08101016A HK 1107768 A1 HK1107768 A1 HK 1107768A1
Authority
HK
Hong Kong
Prior art keywords
oral use
solid drug
drug
solid
oral
Prior art date
Application number
HK08101016.0A
Other languages
English (en)
Inventor
Tsuyoshi Naganuma
Mitsuo Muramatsu
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32588229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1107768(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of HK1107768A1 publication Critical patent/HK1107768A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK08101016.0A 2002-12-16 2006-05-08 Solid drug for oral use HK1107768A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002364238 2002-12-16
HK06105339A HK1085131A1 (en) 2002-12-16 2006-05-08 Solid drug for oral use

Publications (1)

Publication Number Publication Date
HK1107768A1 true HK1107768A1 (en) 2008-04-18

Family

ID=32588229

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08101016.0A HK1107768A1 (en) 2002-12-16 2006-05-08 Solid drug for oral use
HK06105339A HK1085131A1 (en) 2002-12-16 2006-05-08 Solid drug for oral use

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK06105339A HK1085131A1 (en) 2002-12-16 2006-05-08 Solid drug for oral use

Country Status (24)

Country Link
US (2) US20060018959A1 (pl)
EP (2) EP1574215B1 (pl)
JP (1) JP4633469B2 (pl)
KR (2) KR101072909B1 (pl)
CN (2) CN100339078C (pl)
AU (1) AU2003289320C1 (pl)
BR (1) BR0317349A (pl)
CA (1) CA2507002C (pl)
EA (1) EA008196B1 (pl)
ES (1) ES2544560T3 (pl)
HK (2) HK1107768A1 (pl)
HR (1) HRP20050544B1 (pl)
IL (1) IL169040A (pl)
IS (1) IS7929A (pl)
ME (2) ME00076B (pl)
MX (1) MXPA05006513A (pl)
NO (1) NO20053467L (pl)
NZ (1) NZ540664A (pl)
PL (1) PL220457B1 (pl)
RS (1) RS58025B1 (pl)
TW (2) TWI382838B (pl)
UA (2) UA84694C2 (pl)
WO (1) WO2004054574A1 (pl)
ZA (1) ZA200504613B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1930123B (zh) * 2004-03-05 2010-06-23 橘生药品工业株式会社 用于预防或治疗伴有神经障碍的膀胱过度活动症的医药组合物
WO2006038611A1 (ja) * 2004-10-05 2006-04-13 Kissei Pharmaceutical Co., Ltd. 下部尿路閉塞疾患に伴う蓄尿障害の予防及び／又は治療剤
US20080242717A1 (en) * 2007-02-28 2008-10-02 Fumiyasu Sato Methods for treating benign prostatic hyperplasia
TW200900094A (en) * 2007-03-13 2009-01-01 Takeda Pharmaceutical Solid preparation
WO2012000926A1 (de) 2010-06-28 2012-01-05 Ratiopharm Gmbh Silodosin-cyclodextrin einschlussverbindungen
JP2013532651A (ja) 2010-07-23 2013-08-19 ラティオファルム ゲー・エム・ベー・ハー シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品
ES2492673T3 (es) 2010-12-23 2014-09-10 Sandoz Ag Formas cristalinas de un ingrediente farmacéutico activo
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
WO2013061338A1 (en) 2011-08-24 2013-05-02 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
JP6031722B2 (ja) * 2011-08-31 2016-11-24 国立大学法人 千葉大学 女性の排尿障害の治療剤
JP6215238B2 (ja) * 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
RS57795B1 (sr) 2012-07-16 2018-12-31 Fibrogen Inc Kristalni oblici inhibitora prolil hidroksilaze
EP2979697A4 (en) 2013-03-26 2016-11-30 Kissei Pharmaceutical PREPARATION FOR ORAL ADMINISTRATION WITH MASKED BITTERNITY OF SILODOSINE
KR20210104173A (ko) 2013-06-06 2021-08-24 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
KR102206104B1 (ko) * 2014-04-03 2021-01-22 한미약품 주식회사 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
CN103933001A (zh) * 2014-05-09 2014-07-23 浙江华海药业股份有限公司 一种稳定的赛洛多辛口服固体药物组合物及其制备方法
CN105435233B (zh) * 2014-08-06 2018-05-01 江苏正大丰海制药有限公司 一种英加韦林的药物组合物
JP6366547B2 (ja) * 2015-08-03 2018-08-01 大原薬品工業株式会社 光安定性が向上した、プラミペキソール製剤包装体
CN108685867A (zh) * 2017-04-06 2018-10-23 昆明积大制药股份有限公司 一种赛洛多辛薄膜衣片及其制备方法
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
CN111437260A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 用于制备盐酸美金刚固态药物组合物的方法
JP7262005B2 (ja) * 2019-01-25 2023-04-21 日本ジェネリック株式会社 シロドシン含有固形組成物及びその製造法
CN114601826B (zh) * 2022-03-31 2024-06-04 乐泰药业有限公司 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060073A (en) 1963-03-02 1967-02-22 Benger Lab Ltd 2,2,2-trichlorethyl hydrogen succinate and salts
US4547498A (en) 1983-01-06 1985-10-15 Mylan Pharmaceuticals Inc. Pharmaceutical combination composition and associated method
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
HU200926B (en) * 1988-10-28 1990-09-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
DE122010000031I1 (de) * 1992-12-02 2010-10-21 Kissei Pharmaceutical Indolin Verbindungen zur Behandlung von Dysurien
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
RU2130311C1 (ru) 1994-05-06 1999-05-20 Пфайзер Инк. Лекарственные формы азитромицина с контролируемым высвобождением
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
WO1999015202A1 (fr) * 1997-09-22 1999-04-01 Kissei Pharmaceutical Co., Ltd. Medicaments contre la dysurie resultant d'une hypertrophie de la prostate
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
US20010053780A1 (en) 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
JP4014068B2 (ja) * 1999-07-28 2007-11-28 芦森工業株式会社 エアバッグ装置
PE20011178A1 (es) * 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
US6849655B2 (en) * 2000-05-15 2005-02-01 Kissei Pharmaceutical Co., Ltd. Aqueous liquid formulations
DK1353696T3 (da) * 2001-01-26 2007-04-10 Schering Corp Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivator(er) og sterolabsorptionsinhibitor(er) og behandlinger til vaskulære indikationer
JP2001288115A (ja) 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
JPWO2002069957A1 (ja) * 2001-03-01 2004-07-02 グレラン製薬株式会社 フェノフィブラート含有組成物
US6786714B2 (en) * 2001-04-12 2004-09-07 James W. Haskew Delivery system for liquid catalysts
GB0113843D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same

Also Published As

Publication number Publication date
ZA200504613B (en) 2006-08-30
KR20050084316A (ko) 2005-08-26
RS20050470A (en) 2007-09-21
TW200418457A (en) 2004-10-01
WO2004054574A1 (ja) 2004-07-01
AU2003289320B2 (en) 2008-08-21
CN100339078C (zh) 2007-09-26
EA008196B1 (ru) 2007-04-27
IL169040A (en) 2013-04-30
US20120064154A1 (en) 2012-03-15
UA85359C2 (ru) 2009-01-12
CN1726028A (zh) 2006-01-25
TWI382838B (zh) 2013-01-21
NO20053467L (no) 2005-07-15
KR101077061B1 (ko) 2011-10-26
US20060018959A1 (en) 2006-01-26
TW200944200A (en) 2009-11-01
CN101069685B (zh) 2011-12-14
EP1574215A4 (en) 2009-07-01
HRP20050544A2 (en) 2006-09-30
EP2402010A1 (en) 2012-01-04
HRP20050544B1 (hr) 2017-12-01
CN101069685A (zh) 2007-11-14
RS58025B1 (sr) 2019-02-28
AU2003289320A1 (en) 2004-07-09
TWI325318B (en) 2010-06-01
KR20100133024A (ko) 2010-12-20
EP1574215B1 (en) 2015-07-15
UA84694C2 (ru) 2008-11-25
ME00076B (me) 2011-02-10
EA200500985A1 (ru) 2005-12-29
KR101072909B1 (ko) 2011-10-17
NZ540664A (en) 2007-09-28
IS7929A (is) 2005-07-01
BR0317349A (pt) 2005-11-16
ES2544560T3 (es) 2015-09-01
JP4633469B2 (ja) 2011-02-16
CA2507002A1 (en) 2004-07-01
AU2003289320C1 (en) 2018-09-06
MEP10808A (en) 2010-06-10
EP1574215A1 (en) 2005-09-14
MXPA05006513A (es) 2005-09-08
PL220457B1 (pl) 2015-10-30
CA2507002C (en) 2012-09-18
JPWO2004054574A1 (ja) 2006-04-20
HK1085131A1 (en) 2006-08-18
PL377495A1 (pl) 2006-02-06

Similar Documents

Publication Publication Date Title
HK1085131A1 (en) Solid drug for oral use
GB0217225D0 (en) Medicinal compounds
GB0225540D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0225535D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
GB0225030D0 (en) Medicinal compounds
GB0218625D0 (en) Pharmaceutical compounds
GB0210397D0 (en) Pharmaceutical formulations
GB2394894B (en) New use for pharmaceutical composition
EP1553925A4 (en) ORAL DOSAGE FORM WITH MODIFIED RELEASE
GB0215775D0 (en) Pharmaceutical compounds
GB2392093B (en) Pharmaceutical formulations
GB0206505D0 (en) Pharmaceutical combination
PL373409A1 (pl) Kombinacja farmaceutyczna
EP1614417A4 (en) SOLID PREPARATION FOR ORAL USE
GB0220451D0 (en) Pharmaceutical use
GB0225536D0 (en) Medicinal compounds
GB0224508D0 (en) Medicinal compounds
GB0225541D0 (en) Medicinal compounds
GB0209482D0 (en) Medicinal compounds
GB0225538D0 (en) Medicinal compounds
GB0225031D0 (en) Medicinal compounds
GB0225027D0 (en) Medicinal compounds
GB0215930D0 (en) Medicinal compounds

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231210